XML 103 R3.htm IDEA: XBRL DOCUMENT v3.20.1
Consolidated Balance Sheets (Parentheticals) - USD ($)
$ / shares in Thousands, $ in Thousands
Dec. 31, 2019
Dec. 31, 2018
Unrestricted cash and cash equivalents $ 135,379 $ 60,968
Restricted cash and cash equivalents 41,015 80,786
Loans, interest and fees receivable, at fair value 4,386 6,306
Loans, interest and fees receivable, gross 998,209 541,344
Allowances for uncollectible loans, interest and fees receivable (186,329) (79,211)
Deferred revenue (90,307) (43,897)
Notes payable, at face value $ 749,209 $ 390,927
Common stock, par value (in dollars per share) $ 0 $ 0
Common stock, authorized (in shares) 150,000,000 150,000,000
Common stock, issued (in shares) 15,885,314 15,563,574
Common stock, outstanding (in shares) 15,885,314 15,563,574
Own-share lending arrangement, outstanding (in shares) 1,459,233 1,459,233
Series A Preferred Stock [Member]    
Preferred stock, par value (in dollars per share) $ 0 $ 0
Preferred stock, shares authorized (in shares) 10,000,000 0
Preferred stock, shares issued (in shares) 400,000 0
Preferred stock, shares outstanding (in shares) 400,000 0
Variable Interest Entity, Primary Beneficiary [Member]    
Unrestricted cash and cash equivalents $ 78,700 $ 16,800
Restricted cash and cash equivalents 25,900 61,000
Loans, interest and fees receivable, at fair value 3,900 5,700
Loans, interest and fees receivable, gross 857,200 403,400
Allowances for uncollectible loans, interest and fees receivable (168,800) (57,400)
Deferred revenue (40,700) (13,200)
Notes payable, at face value $ 701,100 $ 366,700